Mirvetuximab Soravtansine is a targeted cancer medication designed to treat ovarian, peritoneal, and fallopian tube cancers. It works by specifically targeting cancer cells that have high levels of a protein called folate receptor-alpha on their surface. This medication delivers anti-cancer agents directly to the tumor cells while aiming to minimize damage to healthy cells.

Investigator’s Choice of Chemotherapy refers to standard chemotherapy treatments that doctors can select based on what they believe will work best for individual patients. These are conventional cancer treatments that work by killing rapidly dividing cells throughout the body.

Both treatments are used in patients whose cancer has become resistant to platinum-based chemotherapy treatments, but they work in different ways. While mirvetuximab soravtansine targets specific cancer cells, standard chemotherapy affects all rapidly growing cells in the body.

Ovarian Cancer – A disease that begins in the ovaries, which are part of the female reproductive system. The cancer develops when abnormal cells in the ovaries start to multiply uncontrollably and form tumors. It typically spreads first within the pelvis and abdomen.

Primary Peritoneal Cancer – A rare cancer that develops in the peritoneum, which is the thin, delicate lining that covers the inside wall of the abdomen and most of the organs within it. The cancer cells grow and spread along the surfaces of the peritoneal cavity. This cancer behaves similarly to ovarian cancer.

Fallopian Tube Cancer – A cancer that develops in the fallopian tubes, which are the ducts that connect the ovaries to the uterus. The cancer begins when cells in the fallopian tubes develop mutations and grow out of control. The disease process is very similar to ovarian cancer in terms of how it develops and spreads.